Menu
We have a long history of working with clients on corporate (M&A, JVs and alliances) and business development (licensing) transactions. We advise clients on portfolio and lifecycle management, global product launches, sales force effectiveness, regional growth strategies and regulatory issues. We help them develop solid R&D strategies, institutionalise innovation and help them assess technology platforms.
(e.g., orphan drugs, drug delivery, legacy products)
We advise clients and investors on value-maximization strategies in the specialty pharma universe, for example, building on specialty pharma companies’ core strengths, strategies to develop services linked to products and the resolution of regulatory issues. We have written books in the specialty pharma sector, e.g., ‘The Generics Fascination’ published by Handelsblatt Publishing Group.
Together with biotechnology clients, we develop portfolio growth and licensing strategies. We advise clients on how to approach potential partners and investors while building an overall track record that will appeal to public markets in view of an initial public offering (IPO).
We advise clients on growth options (incl. M&A) and operational improvement programs, e.g., applying our proprietary pharmaceutical production software, and evaluate changes in various regulatory environments. Our insights into their pharmaceutical customers allow us to focus on the development and improvement of the specialist services contract service providers have to offer in order to be successful.
We help clients evaluate growth opportunities from new technologies, companion diagnostics to pharmaceutical products, regional expansion, or ongoing consolidation in the industry.
We assist clients in identifying and pursuing new business areas, products and regions and advise them on the acquisition of technologies and on M&A opportunities. We also help clients successfully differentiate their pricing structures in order to escape price pressure from purchasing groups that continue to play a major role among medical device customers.
In healthcare services, many challenges and opportunities result from the specific regulations in the healthcare systems and their reforms. Having dived deeply into many healthcare systems by country and therapeutic area, we continue to be intrigued by the opportunities arising from increased privatisation, the high sensitivity of business success to minor adjustments to the business model and the increased sophistication of payors, in particular well-incentivized statutory health insurance or occupational health players.
We advise acute care players on growth, operational improvement programs, and consolidation issues, taking into account the changing regulatory environment and building on many years of advanced thinking about effective acute care.
We help clients to increase margins and pursue targeted M&A strategies. Our extensive experience in the nursing care market provides deep insights into the political, regulatory, economics and sociocultural factors determining success.
We help clients to identify high-margin segments and growth segments, as well as M&A consolidation strategies
Sign up for latest deals & insights
English 
Deutsch